clinical research in the future. 
英文關鍵詞： Thrombolysis, Recombinant tissue plasminogen 
activator (rtPA), Magnetic nanocarriers, Magnetic 
targeting, Targeting therapy 
 
 2
目  錄 
中 文 摘 要 ---------------------------------------------------------------------------------------------------- 3 
 
ABSTRACT ------------------------------------------------------------------------------------------------------ 4 
 
1. Introduction ------------------------------------------------------------------------------------------------- 4 
 
2. Materials and methods ------------------------------------------------------------------------------------ 4 
 
2.1. Materials ----------------------------------------------------------------------------------------------------- 5 
 
2.2. Bioconjugation of rtPA on MNCs --------------------------------------------------------------------------5  
 
2.3. Characterization of MNCs and binding capacity of rtPA ----------------------------------------------5 
 
2.4. Activity and stability assays for MNC-rtPA --------------------------------------------------------------6 
 
2.5. Kinetics of the free-rtPA and MNC-rtPA ------------------------------------------------------------------6 
 
2.6. In vitro cytotoxicity study -----------------------------------------------------------------------------------6 
 
2.7. In vitro thrombolysis ----------------------------------------------------------------------------------------7 
 
3. Results -------------------------------------------------------------------------------------------------------- 7 
 
3.1. Characterization of MNCs --------------------------------------------------------------------------------- 7 
 
3.2. Quantification and activity of MNC-rtPA and thermal stability -------------------------------------- 8 
 
3.3. Study of drug kinetics --------------------------------------------------------------------------------------- 8 
 
3.4. In vitro cytotoxicity test --------------------------------------------------------------------------- --------- 8 
 
3.5. In vitro thrombolysis study --------------------------------------------------------------------------------- 8 
 
4. Discussion ---------------------------------------------------------------------------------------------------- 9 
 
5. Conclusions ------------------------------------------------------------------------------------------------ 10 
 
Acknowledgements ----------------------------------------------------------------------------------------- 10 
 
Reference -------------------------------------------------------------------------------------------------------- 10 
 
學術期刊發表 -------------------------------------------------------------------------------------------------- 13 
 
國科會補助專題研究計畫成果報告自評表 -------------------------------------------------------------- 14 
 
國科會補助專題研究計畫項下出席國際學術會議心得報告(曾紳睿同學) ----------------------- 16 
 4
 
ABSTRACT 
 
Low-toxicity magnetic nanocarriers (MNCs) with a shell of poly[aniline-co-N-(1-one-butyric 
acid) aniline] (SPAnH) and a core of Fe3O4 magnetic nanoparticles (MNPs) were successfully 
developed to carry the recombinant tissue plasminogen activator (rtPA) to form MNC-rtPA for 
targeted therapy of thrombolysis in rat. The average diameter of MNCs was 14.8 nm with 
superparamagnetic properties. A maximum effective dose of 276.2 μg rtPA could be immobilized on 
one mg of MNCs, and the stability of MNC-rtPA was more stable than that of free-rtPA when kept at 
4 °C and 25 °C. The designing and delivering of MNC-rtPA to enhance efficiency of thrombolysis 
therapy by applying an extra magnetic field were demonstrated in vitro and in vivo in blood-clot tube 
and in animal models, respectively. In in vitro thrombolysis test, the MNC-rtPA could be guided to 
clot site by an extra magnetic field to significantly short the clot lysis time (10.8 ± 4.2 min) 
compared to free-rtPA (39.2 ± 3.2 min). This system designed based on magnetic targeting could 
significantly accelerate thrombolysis in vitro and may be useful in clinical research in the future.  
 
Key words: Thrombolysis, Recombinant tissue plasminogen activator (rtPA), Magnetic nanocarriers, 
Magnetic targeting, Targeting therapy 
 
1. Introduction 
 
Thrombotic diseases such as acute myocardial infarction (AMI) and ischemic stroke are the 
leading causes of death and disability in developed countries. The patients who have the thrombotic 
diseases always due to the most plasmin are rapidly inactivated by α2-plasmin inhibitor in plasma [1]. 
Some fibrinolytic agents, such as urokinase (UK), streptokinase (SK), and rtPA, are used widely for 
clinically thrombolytic therapy to lyse occlusive blood clots and restore the vascular flow [2, 3]. 
rtPA is a serine protease composed of 530 amino acids secreted into the bloodstream by vascular 
endothelial cells [4]. The rtPA does not dissolve the blood clots directly; the enzyme catalyzes 
conversion of the plasminogen into active protease (plasmin) which efficiently degrades fibrin of 
blood clots [5]. However, rtPA cannot be conveyed to the blood clot site after injection due to the 
vascular flow is slow in the obstructive blood vessel. In order to restore the flow efficiently, the dose 
of rtPA must be increased but the excessive rtPA in plasma may cause serious hemorrhagic 
complications. Approximately 50% of patients can restore the vascular flow within 90 min with rtPA 
by intravenous injection for thrombolytic therapy but about 20% of patients show serious side 
effects in the form of bleeding [6, 7]. Therefore, new approaches to treat thrombotic patients are 
needed. Currently, new drug delivery systems are used widely to reduce the side-effects of 
fibrinolytic agents and enhance their stability during storage and blood circulation. Such systems 
include encapsulating fibrinolytic drugs (i.e. tissue plasminogen activator (tPA) or rtPA or SK or 
UK) into liposomes [8] or polymeric nanoparticles [9] or magnetic carriers [10–14] as drug carriers 
to increase the efficiency of thrombolytic therapy. 
Magnetic nanocarriers (MNCs) for drugs are usually composed of the iron oxide core with 
superpapramagnetic properties and a shell of hydrophilic polymers providing high-capacity 
functionalized surfaces capable of binding enzymes [15], inhibiting aggregation, and increasing 
stability [16, 17]. They can also be used for a variety of biomedical applications, such as 
contrast-enhancing agents for magnetic resonance imaging (MRI) [18, 19], magnetically guided 
drug targeting [10, 11, 20], enhancing enzyme stability for repeated use [15, 21, 22], and magnetic 
diagnosis [23]. They also exhibit high drug loading capacities and good stabilities in aqueous 
solutions, and excellent biocompatibilities with cells and tissues when used for drug delivery 
[24–31].  
We recently demonstrated the feasibility of targeting strategies for thrombolysis therapy in a rat 
embolic model, using polyacrylic acid (PAA)-coated magnetic nanoparticles  (PAA/MNPs) as the 
 6
inductively-coupled plasma optical emission spectrometry (720-ES, Varian Inc., Palo Alto, CA, 
USA). The binding capacity of rtPA immobilized on MNCs was calculated by measuring unbound 
rtPA concentration in the supernatant and washing solution; binding capacity was expressed as the 
amount of rtPA (μg) bound per mg of MNCs. The concentration was determined by a colorimetric 
method by a spectrophotometer (America/Thermo, model 20 Genesys) at 595 nm with the Protein 
Assay Kit from Bio-Rad as described previously [33]. 
 
2.4. Activity and stability assays for MNC-rtPA 
 
The activity of rtPA was measured spectrophotometrically by using the specific chromogenic 
substrate (S-2288TM) for rtPA. Fifty μL of MNC-rtPA solution were reacted with 350 μL Tris-buffer 
(pH = 8.4) and 200 μL S-2288TM at 25 °C for 30 s, then the reaction was stopped by adding 100 μL 
acetic acid (20 wt%). The absorbance of ρ-nitroaniline (ρ-Na) was measured at 405 nm (OD405) by 
spectrophotometer. The activity (U) of each sample was calculated as follows: OD405 × 0.104 × total 
volume (mL)/reaction time (min). The relative activity after bioconjugation was defined as the 
percentage of the specific activity (U/mg) of MNC-rtPA compared to that of free-rtPA at 25 °C. The 
stabilities of free-rtPA and MNC-rtPA stored at 4 °C and 25 °C for 1–35 days were also analyzed 
using the above activity assay method. The reaction mechanism between rtPA and S-2288TM was 
following: 
 
 
2.5. Kinetics of the free-rtPA and MNC-rtPA 
 
The kinetic parameters of free-rtPA and MNC-rtPA were studied by initial rate method with 
Michaelis constant [34]. The rtPA were reacted with different concentrations of S-2288TM (0.1–1.0 
mM) at 25 °C to calculate the Km and Vmax values, where Vmax was the highest possible reaction 
velocity when rtPA was saturated with the substrate and Km was the Michaelis constant represented 
the substrate concentration that yielded (half the true maximum reaction velocity) and exhibited 
effective affinity between rtPA and substrate. The Km and Vmax values were calculated using 
following equations [34]: 
 
where v and Vmax are the initial and maximum reaction velocity respectively, [S] is the concentration 
of S-2288TM, [P] is the concentration of ρ-Na. 
 
2.6. In vitro cytotoxicity study 
 
HUVEC were cultured in M199 supplemented with 2.2 mg/mL sodium bicarbonate, 10% FBS, 
50 μg/mL gentamycin, 50 μg/mL penicillin, 50 μg/mL streptomycin, 25 U/mL heparin and 30 
μg/mL ECGS at 37 °C and 5% CO2 for 48 h. Approximately 10,000 cells (i.e., 150 μL of a 
suspension of 6.67 × 104 cells/mL) were placed in each well which coated 1 % gelatin of a 96-well 
culture plate and incubated in a humidified chamber at 37 °C and 5% CO2 for 48 h. Fifty μL of 
different concentrations of MNCs in M199 were added and the culture continued. Cell cultures were 
 8
absorption peaks at 320–330 nm (π–π* transition of benzenoid ring) and 596 nm (exction of quinone 
ring) for SPAnNa were obtained. By HCl-doping and self-acid-doping, SPAnNa was changed to 
SPAnH and two new absorption peaks at 400–450 nm (polaron band) and 926 nm (bipolaron band) 
were appeared. The ESR signal (Fig. 2E) showed that the peak-to-peak line width (ΔHpp) was 2.49 G, 
the spin density (Ns) was 3.04 × 1020 spin/g and the g value was 2.0037 which confirmed the 
resonance of free electrons delocalized in the π-system of the carbon atoms forming SPAnH 
backbone in the main chain [36]. The result indicated that many electron-hole pairs were produced 
on the main chain of SPAnH, resulting in the carriers with positive charges.  
 
3.2. Quantification and activity of MNC-rtPA and thermal stability 
 
The quantity of rtPA binding on MNCs was measured by chromogenic substrate assay as shown 
in Fig. 3A. The quantity of rtPA immobilized one mg of MNCs increased with increasing 
concentrations of added rtPA. A maximum of 429.98 μg of rtPA could be bound to one mg of MNCs. 
However, the specific activity of MNC-rtPA was decreased with increasing concentrations of added 
rtPA. When the quantities of rtPA bound to 1 mg of MNCs were increased from 131.50 μg to 429.98 
μg, the specific activities decreased from 82% to 52.8%, respectively.  
The thermal stabilities of free- and MNC-rtPA in DI water after storage at 4 °C and 25 °C with 
time were measured using substrate assay (Fig. 3B). The specific activity of free-rtPA lost its 
original activity after 21 days of storage at 25 °C, but the MNC-rtPA maintained 73% of its initial 
activity at 35 days. When stored at 4 °C for 35 days, free- and MNC-rtPA still maintained about 32% 
and 80% of their initial activities, respectively.  
 
3.3. Study of drug kinetics 
 
The kinetic parameters of free- and MNC-rtPA, Vmax and Km, were assayed using S-2288TM as 
substrate agent (shown in Fig. 4) and calculated from Line Weaver–Burk plots. Vmax was defined 
that the maximum reaction velocity when rtPA was saturated with the substrate. Km was defined that 
as the concentration of substrate that yielded a half the reaction velocity [34]. The Vmax of free-rtPA 
was 7.12 U/mg rtPA, which was higher than that of MNC-rtPA (5.95 U/mg rtPA), whereas the Km 
for S-2288TM of the MNC-rtPA (4.39 mM) was higher than that of free-rtPA (3.50 mM). The 
affinity between rtPA and substrate was decreasing with increasing the Km value. These data 
indicated that the affinity between MNC-rtPA and substrate decreased in comparison with free-rtPA. 
This result might relate to the steric effects and the freedom of activity site was limited while rtPA 
immobilized on the surface of MNC. Therefore, the activity sites of MNC-rtPA were not easy to 
approach the substrate. 
  
3.4. In vitro cytotoxicity test 
 
The cytotoxicities of MNCs to HUVEC were derived by the XTT assay method. The cell 
viability after 48 h incubation with MNCs at different concentrations, demonstrating that the 
HUVEC co-cultured with MNCs remained viable compared with the control when the 
concentrations were increased up to 150 μg/mL and even at an applied magnetic field under the 
culture plates (Fig. 5A). Furthermore, the cytotoxicity was confirmed by fluorescence microscopy 
by HUVEC co-cultured with MNCs propagated continuously over a 7-day culture period, the cell 
viability and growth rate were not different as compared to the control (Fig. 5B). The results 
indicated that MNCs had good biocompatibility and low toxicity to cells. 
 
3.5. In vitro thrombolysis study 
 
The in vitro thrombolysis of clots in non-circulating state was tested by adding MNCs, 
free-rtPA and MNC-rtPA (Fig. 6). The efficiency of thrombolysis was determined by measuring the 
absorbance of suspension at 405 nm (OD405) after 30 min of reaction. The control (Fig. 6A) and 
MNCs (Fig. 6D) groups did not display any thrombolysis for blood clots, even at an applied 
 10
between rtPA and substrate was decreasing with higher Km value. These data indicated that the 
affinity between MNC-rtPA and substrate decreased in comparison with free-rtPA. This result might 
relate to the steric effects, structural changes and the limited freedom of activity site while rtPA was 
immobilized on the surface of MNCs, resulting in the lower accessibility between the substrate and 
activity sites of MNC-rtPA [42]; even so, the thermal stability of rtPA was enhanced. The whole 
efficacy of thrombolysis of MNC-rtPA still overmatched that of free-rtPA because of the MNC-rtPA 
would be guided rapidly to the clot site and enhance the concentration there. 
In in vitro thrombolysis of non-circulating state, the hemachrome of lysed clot for MNC-rtPA 
was similar to that of free-rtPA. It indicated that the rtPA conjugated on the MNCs still maintaining 
the function of thrombolysis. However, the OD405 obviously increased while a magnetic field was 
applied under the bottles during thrombolysis reaction. This phenomenon was most likely that most 
MNC-rtPA was guided and concentrated on the bottom of bottles and would not suspend while 
shaking, resulting in most MNC-rtPA spread around the clots closely. Therefore, more blood clot 
could be degraded by the plasminogen of clots and activated to plasmin rapidly. In order to precisely 
simulate the state of in vivo thrombolysis, the in vitro circulating thrombolysis was designed to test 
the efficiency of magnetic targeting and clot lysis. The clot lysis time for MNCs group was similar 
to that of control group. It indicated that MNCs did not display any effects for thrombolysis. 
However, the lysis time was shortened ~29 min by magnetically targeted therapy of MNC-rtPA 
comparing to that by free-rtPA. The results attributed to the slow flow rate induced by the export of 
right-channel with clot, resulting in majority of mobile solution (PPP) flowed out from cushioned 
export of left-channel and the free-rtPA at injection site just could not arrive efficiently and rapidly 
to the clot. However, the MNC-rtPA could be guided efficiently from injection site to the clot and 
concentrated around the clot to activate plasminogen to plasmin to dissolve the clot rapidly. It 
indicated this platform which carried rtPA by MNCs could enhance the drug delivery for 
thrombolysis and be a consultation for in vivo study. 
 
5. Conclusions 
 
In this study, a non-specific plasminogen activator rtPA was conjugated with MNCs and 
became a targeted thrombolytic agent, which could successfully accelerate thrombolysis in 
clot-occluded tube and animal models by an applied magnetic field. The advanced MNCs had high 
capacity of rtPA and enhanced the thermal stability of rtPA. The MNC-rtPA have the shortest clot 
lysis time (10.8 ± 4.2 min) in tube model and rapidly restore the blood flow by about 80% compared 
to clot obstruction within 25 min in rat model. It demonstrated that magnetically targeted 
thrombolysis could avoid hemorrhagic complications and have great potential for the clinical 
treatment of thrombosis. 
 
Acknowledgements 
We thank the National Science Council of the Republic of China, Chang Gung Memorial 
Hospital, and Ministry of Economic Affairs for financial aid (NSC 99-2221-E-182-068-, NSC 
94-2216-E-182-001, CMRPD2A0041, and A356AE1120). The authors very thank Dr. Ying-Shiung 
Lee and Prof. Yu-Sun Chang, who started the nano-magnetic drug project in Chang Gung Memorial 
Hospital and Chang Gung University, Chang Gung Molecular Medicine Research Center five years 
ago, and Chang Gung Memorial Hospital Microscopy Core Laboratory. 
 
Reference 
  
[1] Harpel PC, Chang TS, Verderber E. Tissue Plasminogen Activator and Urokinas Meediate the 
Binding of Glu-Plasminogen to Plasma Fibrin I. J Biol Chem 1985;260:4432-40. 
[2] Marder V. Thrombolytic therapy. Blood Rev 2001;15:143–57. 
[3] Andersen HR, Nielsen TT, et al. A comparison of coronary angioplasty with fibrinolytic 
therapy in acute myocardial infarction. N Engl J Med 2003;349:733–42. 
[4] Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective 
modification of the biological functions. Cardiovascular Research 1995;30:255-61. 
 12
[25] Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles 
and their intracellular uptake into human cancer cells. Langmuir 2005;21:8858–64. 
[26] Zhang JL, Srivastava RS, Misra RDK. Core–shell magnetite nanoparticles surface encapsulated 
with smart stimuli-responsive polymer: Synthesis, characterization, and LCST of viable 
drug-targeting delivery system. Langmuir 2007;23:6342–51. 
[27] Zhang Y, Zhang J. Surface modification of monodisperse magnetite nanoparticles for improved 
intracellular uptake to breast cancer cells. J Colloid Interface Sci 2005;283:352–7. 
[28] Hu F, Li Z, Tu C, Gao M. Preparation of magnetite nanocrystals with surface reactive moieties 
by one-pot reaction. J Colloid Interface Sci 2007;311:469–74. 
[29] Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, et al. 
Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. 
Biomaterials 2010;31:7735–63. 
[30] Hua MY, Liu HL, Yang HW, Chen PY, Tsai RY, Huang CY, et al. The effectiveness of a 
magnetic-nanoparticle-based delivery system for BCNU in the treatment of gliomas. 
Biomaterials 2011;32:516–27. 
[31] Yang HW, Hua MY, Liu HL, Huang CY, Tsai RY, Lu YJ, et al. Self-protecting core-shell 
magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. 
Biomaterials 2011;32:6523–32. 
[32] Fang N, Tan WJ, Leong KW, Mao HQ, Chan V. pH responsive adhesion of phospholipid 
vesicle on poly(acrylic acid) cushion grafted to poly(ethylene terephthalate) surface. Colloids 
Surf B Biointerfaces 2005;42:245–52. 
[33] Kouassi G, Irudayaraj J, McCarty G. Examination of cholesterol oxidase attachment to 
magnetic nanoparticles. J Nanobiotechnol 2005;3:1–9. 
[34] Ye P, Xu ZK, Che AF, Wu J, Seta P, Chitosan-tethered poly(acrylonitrile-co-maleic acid) 
hollow fiber membrane for lipase immobilization. Biomaterials 2005;26:6394-403. 
[35] Ma HL, Qi XR, Maitani Y, Nagai T. Preparation and characterization of superparamagnetic iron 
oxide nanoparticles stabilized by alginate. Int J Pharm 2007;333:177–86. 
[36] Sánchez RD, Ramos CA, Rivas J, Vaqueiro P, López-Quintela MA. Ferromagnetic resonance 
and magnetic properties of single-domain particles of Y3Fe5O12 prepared by sol–gel method. 
Phys Rev B Condens Matter 2004;354:104–7. 
[37] Luthra V, Singh R, Gupta SK, Mansingh A. Mechanism of dc conduction in polyaniline doped 
with sulfuric acid. Current Applied Physics 2003;3:219–22. 
[38] Liao DL, Wu GS, Liao BQ. Zeta potential of shape-controlled TiO2 nanoparticles with 
surfactants. Colloids Surf A Physicochem Eng Asp 2009;348:270–5. 
[39] Mandzy N, Grulke E, Druffel T. Breakage of TiO2 agglomerates in electrostatically stabilized 
aqueous dispersions. Powder Technol 2005;160:121–6. 
[40] Zhang HZ, Gao FP, Liu LR, Li XM, Zhou ZM, Yang XD, Zhang QQ. Pullulan acetate 
nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy. Colloid Surf 
B-Biointerfaces 2009;71:19-26. 
[41] Wang YS, Liu LR, Jiang Q, Zhang QQ. Self-aggregated nanoparticles of cholesterol-modified 
chitosan conjugate as a novel carrier of epirubicin. Eur Polym J 2007;43:43–51. 
[42] Hong J, Xu D, Gong P, Yu J, Ma H, Yao S. Covalent-bonded immobilization of enzyme on 
hydrophilic polymer covering magnetic nanogels. Micropor Mesopor Mat 2008;109:470–7. 
 14
國科會補助專題研究計畫成果報告自評表 
請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適
合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。
1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估 
█達成目標 
 
2. 研究成果在學術期刊發表或申請專利等情形： 
論文：█已發表 □未發表之文稿 █撰寫中 □無 
專利：□已獲得 □申請中 █撰寫中 □無 
 
A. 撰寫中的學術期刊 (摘要) 
Low-toxicity magnetic nanocarriers (MNCs) with a shell of poly[aniline-co-N-(1-one-butyric 
acid) aniline] (SPAnH) and a core of Fe3O4 magnetic nanoparticles (MNPs) were successfully 
developed to carry the recombinant tissue plasminogen activator (rtPA) to form MNC-rtPA for 
targeted therapy of thrombolysis in rat. The average diameter of MNCs was 14.8 nm with 
superparamagnetic properties. A maximum effective dose of 276.2 μg rtPA could be immobilized 
on one mg of MNCs, and the stability of MNC-rtPA was more stable than that of free-rtPA when 
kept at 4 °C and 25 °C. The designing and delivering of MNC-rtPA to enhance efficiency of 
thrombolysis therapy by applying an extra magnetic field were demonstrated in vitro and in vivo 
in blood-clot tube and in animal models, respectively. In in vitro thrombolysis test, the 
MNC-rtPA could be guided to clot site by an extra magnetic field to significantly short the clot 
lysis time (10.8 ± 4.2 min) compared to free-rtPA (39.2 ± 3.2 min). This system designed based 
on magnetic targeting could significantly accelerate thrombolysis in vitro and may be useful in 
clinical research in the future.  
 
 
B. 此計劃經費補助所發表的學術期刊 
 
5. Hung-Wei Yang1, Mu-Yi Hua1, Hao-Li Liu1, Chiung-Yin Huang, Rung-Ywan Tsai, Yu-Jen Lu, Ju-Yu Chen, 
Hsiang-Jun Tang, Jia-Shin Wu, Han-Yi Hsien, Yu-Sun Chang,  Tzu-Chen Yen, Pin-Yuan Chen*, Kuo-Chen Wei*, 
"Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to 
gliomas", Biomaterials, 32, 6523-6532 (2011). (IF = 7.882, Filtered by Materials Science, Biomaterials, 2/25) (1 
Equal Contribution) 
6. Mu-Yi Hua1,*, Hsiao-Chien Chen1, Cheng-Keng Chuang1, Rung-Ywan Tsai, Jyh-Long Jeng, Hung-Wei Yang, 
Yaw-Terng Chern*, "The intrinsic redox reactions of polyamic acid derivatives and their application in hydrogen 
peroxide sensor", Biomaterials, 32, 4885-4895 (2011). (IF = 7.882, Filtered by Materials Science, Biomaterials, 
2/25) (1 Equal Contribution) 
7. Mu-Yi Hua*, Hsiao-Chien Chen, Rung-Ywan Tsai, and Chao-Sung Lai, "A novel polybenzimida- zole-modified 
gold electrode for the analytical determination of hydrogen peroxide", Talanta, 85, 631-637 (2011). (IF = 3.722, 
Filtered by Chemistry, Analytical, 11/71) 
8. Mu-Yi Hua*, Chun-Jen Chen, Hsiao-Chien Chen, Rung-Ywan Tsai, Wen Cheng, Chun-Lin Cheng, Yin-Chih Liu, 
"Preparation of a porous composite film for the fabrication of a highly sensitive hydrogen peroxide sensor", 
Sensors, 11, 5873-5885 (2011). (IF = 1.771, Filtered by Instruments & Instrumentation, 14/61) 
 
 16
國科會補助專題研究計畫項下出席國際學術會議心得報告 
                               日期： 100 年 06 月 20 日 
一、 參加會議經過 
2011 TechConnect World Conference & Expo. 會議於美國麻州 Hynes Convention Center 舉
行，會議的時間自 100 年 6 月 13 日至 100 年 6 月 16 日為期四天。此次會議主題內容
涵蓋非常廣，包括 Nano-TechnologyBio-Technology 與 Clean-Tehnology 三大主題，此次會議
本人選擇以海報發表方式報告，因此於 6/06 搭乘長榮航空飛往美國紐約停留4 天後，6/10 再
從美國紐約搭乘美國國鐵前往波士頓。因這次的行程還有實驗室一位學長一同隨行，因此一
路彼此可互相照應，所以我們提早二天到達會議地點，參觀附近的景點，並於 6/13 前往 Hynes 
Convention Center 會場報到領取名牌與會議資料。此會議包含口頭報告與海報發表，且依領
域的不同分成三天進行。且此會議的程序安排非常貼心，將邀請演說及口頭發表與海報發表
的時間錯開，因此並不會衝突到時間，可以多聽到別人的演講及海報，本人之海報被安排於 
6/14 下午四點至六點張貼海報，並於發表海報前解說本人研究內容。在 6/14 至 6/16 期間聆
聽多位學者先進的口頭報告與了解其它學者海報內容，會議於 6/16 圓滿結束。 
二、 與會心得 
這次的國際會議是我第一次參與國際大型會議，雖然一開始會緊張，但隨著時間過去習慣會
場環境以後就比較可以以輕鬆的心態與其他人溝通。此研討會收納的研究內容多元，包含奈
米材料的合成、綠能科技技術、環境科學與生物醫學檢測等等。我這次參加發表題目是 New 
計畫編號 NSC 99-2221-E-182-068- 
計畫名稱 多功能磁性奈米藥物之合成與血栓溶解之應用 
出國人員
姓名 曾紳睿 
服務機構
及職稱 長庚大學化材系/碩士生 
會議時間 
 
100 年 6 月 13 至 
100 年 6 月 16 日 
 
會議地點 
 
美國麻州 Hynes Convention 
Center 
會議名稱 
(中文) 2011 奈米科技世界博覽會 
(英文) 2011 TechConnect World Conference and Expo. 
發表論文
題目 
(中文) 新型 3D 磁性奈米石墨烯氧化物應用於攝護腺癌治療 
(英文) New three-dimensional nanoscale magnetic graphene oxide 
for Prostate Cancer therapy. 
 18
件下，做一小時的退火處理。檢測時在晶片滴上濃度為 0.125 g/mL 的葡萄聚糖 Dextran 內含 1 
wt% 的苯氧葡聚糖 (Phenoxydextran，DexP)，經過 12 小時反應後計算電流的差異，以此做
為定量葡萄糖濃度的依據。 
 
2011/06/16 
(1) A double-based sandwich assay for protein detection in serum based on localized surface 
plasmon resonance 
(2) Antibody immobilization on conductive polymer coated nonwoven fibers for biosensors 
(3) A high-performance VEGF aptamer functionalized polypyrrole nanotube biosensor 
他所用的材料是吡咯 (Pyrrole) 與酸化吡咯 (Pyrrole-3-carboxylic acid) 單體經化學共聚合法
後，成為羧酸化聚吡咯奈米管 (Carboxylated polypyrrole nanotubes)，之後將此材料建構在 
(Field Effect Transistor，FET) 原件上，做為檢測 (Vascular Endothelial Growth Factor，VEGF) 的
生物感測器。作者 J. Jang 在固定化的過程中會先將晶片浸泡在 5 wt% 的 3-氨丙基三甲氧基矽
烷水溶液裡，目的是為了在基材表面產生胺基 -NH2 與聚吡咯奈米管上的羧基 -COOH 做共
價鍵結，等聚吡咯奈米管固定在晶片上後，在滴入濃度為 10 nM 的 VEGF 抗體 40 μL 經過 12
小時的反應，把抗體固定在聚吡咯奈米管上。作者在合成材料過程中製備出兩種不同管徑的
聚吡咯奈米管，分別是直徑~100 奈米與~200 奈米，可得到的最低檢測濃度分別為 4 pM 與
400 fM。 
(4) Specific Protein Detection Using Thermally Reduced Graphene Oxide SheetDecorated with 
Gold Nanoparticle -Antibody Conjugates 
此外，上述這位作者 J.H. Chen 是利用近幾年相當熱門的石墨烯 (Graphene) 來做為 FET 通
道，石墨烯是由碳原子所排列而成的二維網狀結構，具有比奈米碳管還高的電子遷移率，室
溫下約為 15000 cm2/Vs，故對整體感測器的電性能有提升的效果。作者將固定上免疫球蛋白
抗體(Anti-IgG)的奈米金粒子，建構在以石磨烯為通道的 FET 元件上偵測 IgG，從結果中得知
這個感測器的最低可偵測濃度達 2 ng/mL，而且對其他蛋白並無明顯的干擾作用，我認為這是
個未來極具發展潛力的材料。 
 
三、考察參觀活動(無是項活動者略) 
無 
四、建議 
國內的會議很少有像此次會議如此的盛大，而所要請的學者是來自世界各地，如此可以讓大
家的研究交流更快速，並可以聽到不同的見解，更能對自己領域的研究有不一樣的思考。建
議政府或學校應該增加補助碩、博士班的學生出國參加國際性會議的費用，畢竟國外的消費
比國內高出許多，這樣不僅能夠培養學生的國際觀以及學習別人的長處，更可以訓練學生英
文溝通能力，此外，我們也應該要繼續保持著我們的競爭優勢，當然高科技業的發展與前景
 1
國科會補助專題研究計畫項下出席國際學術會議心得報告 
                                   日期： 100 年 06 月 20 日 
一、 參加會議經過 
2011 TechConnect World Conference & Expo. 會議於美國麻州 Hynes Convention Center 舉行，會議的
時間自 100 年 6 月 13 日至 100 年 6 月 16 日為期四天。此次會議主題內容涵蓋非常廣，包括 
Nano-TechnologyBio-Technology 與 Clean-Tehnology 三大主題，此次會議本人選擇以海報發表方式報
告，因此於 6/06 搭乘長榮航空飛往美國紐約停留4 天後，6/10 再從美國紐約搭乘美國國鐵前往波士
頓。因這次的行程還有實驗室一位學長一同隨行，因此一路彼此可互相照應，所以我們提早二天到達
會議地點，參觀附近的景點，並於 6/13 前往 Hynes Convention Center 會場報到領取名牌與會議資料。
此會議包含口頭報告與海報發表，且依領域的不同分成三天進行。且此會議的程序安排非常貼心，將
邀請演說及口頭發表與海報發表的時間錯開，因此並不會衝突到時間，可以多聽到別人的演講及海報，
本人之海報被安排於 6/14 下午四點至六點張貼海報，並於發表海報前解說本人研究內容。在 6/14 至 
6/16 期間聆聽多位學者先進的口頭報告與了解其它學者海報內容，會議於 6/16 圓滿結束。 
二、 與會心得 
這次的國際會議是我第一次參與國際大型會議，雖然一開始會緊張，但隨著時間過去習慣會場環境以
後就比較可以以輕鬆的心態與其他人溝通。此研討會收納的研究內容多元，包含奈米材料的合成、綠
能科技技術、環境科學與生物醫學檢測等等。我這次參加發表題目是 New three-dimensional nanoscale 
magnetic graphene oxide for Prostate Cancer therapy. 
  
計畫編號 NSC 99-2221-E-182-068- 
計畫名稱 多功能磁性奈米藥物之合成與血栓溶解之應用 
出國人員
姓名 曾紳睿 
服務機構
及職稱 長庚大學化材系/碩士生 
會議時間 100 年 6 月 13 至 100 年 6 月 16 日 會議地點 美國麻州 Hynes Convention Center 
會議名稱 
(中文) 2011 奈米科技世界博覽會 
(英文) 2011 TechConnect World Conference and Expo. 
發表論文
題目 
(中文) 新型 3D 磁性奈米石墨烯氧化物應用於攝護腺癌治療 
(英文) New three-dimensional nanoscale magnetic graphene oxide for 
Prostate Cancer therapy. 
 3
(1) A double-based sandwich assay for protein detection in serum based on localized surface plasmon 
resonance 
(2) Antibody immobilization on conductive polymer coated nonwoven fibers for biosensors 
(3) A high-performance VEGF aptamer functionalized polypyrrole nanotube biosensor 
他所用的材料是吡咯 (Pyrrole) 與酸化吡咯 (Pyrrole-3-carboxylic acid) 單體經化學共聚合法後，成為羧
酸化聚吡咯奈米管 (Carboxylated polypyrrole nanotubes)，之後將此材料建構在 (Field Effect Transistor，
FET) 原件上，做為檢測 (Vascular Endothelial Growth Factor，VEGF) 的生物感測器。作者 J. Jang 在
固定化的過程中會先將晶片浸泡在 5 wt% 的 3-氨丙基三甲氧基矽烷水溶液裡，目的是為了在基材表面
產生胺基 -NH2 與聚吡咯奈米管上的羧基 -COOH 做共價鍵結，等聚吡咯奈米管固定在晶片上後，在
滴入濃度為 10 nM 的 VEGF 抗體 40 μL 經過 12 小時的反應，把抗體固定在聚吡咯奈米管上。作者在
合成材料過程中製備出兩種不同管徑的聚吡咯奈米管，分別是直徑~100 奈米與~200 奈米，可得到的
最低檢測濃度分別為 4 pM 與 400 fM。 
(4) Specific Protein Detection Using Thermally Reduced Graphene Oxide SheetDecorated with Gold 
Nanoparticle -Antibody Conjugates 
此外，上述這位作者 J.H. Chen 是利用近幾年相當熱門的石墨烯 (Graphene) 來做為 FET 通道，石墨
烯是由碳原子所排列而成的二維網狀結構，具有比奈米碳管還高的電子遷移率，室溫下約為 15000 
cm2/Vs，故對整體感測器的電性能有提升的效果。作者將固定上免疫球蛋白抗體(Anti-IgG)的奈米金粒
子，建構在以石磨烯為通道的 FET 元件上偵測 IgG，從結果中得知這個感測器的最低可偵測濃度達 2 
ng/mL，而且對其他蛋白並無明顯的干擾作用，我認為這是個未來極具發展潛力的材料。 
 
三、考察參觀活動(無是項活動者略) 
無 
四、建議 
國內的會議很少有像此次會議如此的盛大，而所要請的學者是來自世界各地，如此可以讓大家的研究
交流更快速，並可以聽到不同的見解，更能對自己領域的研究有不一樣的思考。建議政府或學校應該
增加補助碩、博士班的學生出國參加國際性會議的費用，畢竟國外的消費比國內高出許多，這樣不僅
能夠培養學生的國際觀以及學習別人的長處，更可以訓練學生英文溝通能力，此外，我們也應該要繼
續保持著我們的競爭優勢，當然高科技業的發展與前景也需要國家長久的支持與培養人才，才能夠生
生不息。 
五、攜回資料名稱及內容 
無 
六、其他 
99 年度專題研究計畫研究成果彙整表 
計畫主持人：華沐怡 計畫編號：99-2221-E-182-068- 
計畫名稱：多功能磁性奈米藥物之合成與血栓溶解之應用 
量化 
成果項目 實際已達成
數（被接受
或已發表）
預期總達成
數(含實際已
達成數) 
本計畫實
際貢獻百
分比 
單位 
備 註 （ 質 化 說
明：如數個計畫
共同成果、成果
列 為 該 期 刊 之
封 面 故 事 ...
等） 
期刊論文 0 0 100%  
研究報告/技術報告 0 0 100%  
研討會論文 0 0 100% 
篇 
 
論文著作 
專書 0 0 100%   
申請中件數 0 0 100%  專利 已獲得件數 0 0 100% 件  
件數 0 0 100% 件  
技術移轉 
權利金 0 0 100% 千元  
碩士生 3 2 100%  
博士生 2 1 100%  
博士後研究員 0 0 100%  
國內 
參與計畫人力 
（本國籍） 
專任助理 0 0 100% 
人次 
 
期刊論文 4 2 100%  
研究報告/技術報告 0 0 100%  
研討會論文 2 1 100% 
篇 
 
論文著作 
專書 0 0 100% 章/本  
申請中件數 0 0 100%  專利 已獲得件數 0 0 100% 件  
件數 0 0 100% 件  
技術移轉 
權利金 0 0 100% 千元  
碩士生 0 0 100%  
博士生 0 0 100%  
博士後研究員 0 0 100%  
國外 
參與計畫人力 
（外國籍） 
專任助理 0 0 100% 
人次 
 
國科會補助專題研究計畫成果報告自評表 
請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適
合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。
1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估 
■達成目標 
□未達成目標（請說明，以 100 字為限） 
□實驗失敗 
□因故實驗中斷 
□其他原因 
說明： 
2. 研究成果在學術期刊發表或申請專利等情形： 
論文：■已發表 □未發表之文稿 □撰寫中 □無 
專利：□已獲得 □申請中 ■無 
技轉：□已技轉 □洽談中 ■無 
其他：（以 100 字為限） 
此計劃經費補助所發表的學術期刊: 
1.Biomaterials, 32, 6523-6532 (2011). ；  
2.Biomaterials, 32, 4885-4895 (2011). ； 
3.Talanta, 85, 631-637 (2011). ； 
4.Sensors, 11, 5873-5885 (2011). 
3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）（以
500 字為限） 
由於現今因血塊阻塞而導致局部中風或腦中風的病例已越來越多，而目前用於治療此類疾
病的用藥之半衰期通常為 20-30 分鐘 (如 rt-PA)，因此藥物在體內的有效藥量及其現是
有限的，導致無法快速及有效的將血管中的血栓溶解掉，所以常以高濃度的藥物來治療病
患，但卻會導致有出血的風險，因此需要發展可快速集中藥物至血栓處之藥物傳輸系統平
台來克服此難題，目前的大都是使用藥物釋放技術將溶解血栓藥物包覆於藥物載體內，可
緩慢使藥物釋放出來，其優點是可保護藥物避免被體內的酵素分解，延長其藥物半衰期，
其缺點是無法估計藥物釋放的時間與數量且無法快速集中於所需治療部位，因此本發明訴
求不需用介面活性劑、分散劑、交聯劑等有毒性之化學品即可簡單快速製備出具多生物可
反應性官能基之磁性奈米粒子，並將溶解血栓藥物 rt-PA 固定於粒子表面，不僅可延長
藥物的半衰期，並可藉由磁場導引於短時間到達患部且不需等待藥物釋放時間可即時進行
血栓溶解治療，增加局部藥物濃度，在本發明實驗所得知結果，不僅可明顯改善 rt-PA 藥
物之熱穩定性，在 25 ℃ 下儲存 35 day 後，其藥物活性依然保有約 73 %；而純 rt-PA
在 25 ℃儲存 21 day 後，已完全失去其原本之藥物活性，儲存安定性明顯優於純 rt-PA。
且此新藥可以均勻的分散於水中，加上此磁性奈米藥物具有超順磁性，可藉由外加磁場將
